Patent · US Active

Viral complement control proteins for eye disorders

US8043609B2 · kind B2 · utility

10Cited by
13References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 19, 2006
Grant dateOct 25, 2011
Priority date
Expiry dateFeb 18, 2028

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P27/02
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.